Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

43results about How to "Stable intercalation" patented technology

Adriamycin-containing medicine and preparation method thereof

The invention provides adriamycin-containing medicine and a preparation method thereof. The medicine includes a nucleic acid nanoparticle and adriamycin, and the adriamycin is mounted on the nucleic acid nanoparticle; and the nucleic acid nanoparticle includes a nucleic acid structural domain, the nucleic acid structural domain contains an a sequence, a b sequence and a c sequence, and the a sequence contains an a1 sequence or a sequence of the a1 sequence in which at least one base is inserted, missed or replaced, the b sequence contains a b1 sequence or a sequence of the b sequence in whichat least one base is inserted, missed or replaced, and the c sequence contains a c1 sequence or a sequence of the c sequence in which at least one base is inserted, missed or replaced. According to the adriamycin-containing medicine, after the nucleic acid structural domain is modified by a target, targetability is good, adriamycin can be stably delivered, and reliability is high.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

Drug containing tacrine, preparation method for drug, pharmaceutical composition and application of drug

The application provides a drug containing tacrine, a preparation method for the drug, a pharmaceutical composition and application of the drug. The drug comprises a nucleic acid nanoparticle and thetacrine, and the tacrine is deposited on the nucleic acid nanoparticle; the nucleic acid nanoparticle includes a nucleic acid domain; the nucleic acid domain includes an a sequence, a b sequence and ac sequence; the a sequence includes an a1 sequence or a sequence of insertion, deletion or substitution of at least one base of the a1 sequence; the b sequence includes a b1 sequence or a sequence ofinsertion, deletion or substitution of at least one base of the b1 sequence; and the c sequence includes a c1 sequence or a sequence of insertion, deletion or substitution of at least one base of thec1 sequence. After the nucleic acid domain is modified by a target head, the drug containing the tacrine has a relatively good targeting property, can stably deliver the tacrine, and has very high reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

Dihydroartemisinin-containing medicament, preparation method thereof, pharmaceutical composition and application of pharmaceutical composition

The invention provides a dihydroartemisinin-containing medicament, a preparation method thereof, a pharmaceutical composition and an application of the pharmaceutical composition. The medicament comprises nucleic acid nanoparticles and dihydroartemisinin, wherein the dihydroartemisinin is carried on the nucleic acid nanoparticles; the nucleic acid nanoparticles comprise a nucleic acid structural domain, wherein the nucleic acid structural domain comprises a sequence a, a sequence b and a sequence c; the sequence a comprises an a1 sequence or a sequence obtained by insertion, deletion or substitution of at least one base in the a1 sequence; the sequence b comprises a b1 sequence or a sequence obtained by insertion, deletion or substitution of at least one base in the b1 sequence; and the sequence c comprises a c1 sequence or a sequence obtained by insertion, deletion or substitution of at least one base in the c1 sequence. After the nucleic acid structural domain of the dihydroartemisinin-containing medicament provided by the invention is modified by a target head, the medicament can have better targeting property, can stably deliver dihydroartemisinin, and has high reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

Cisplatin-containing medicine, preparation method of cisplatin-containing medicine, medicine composition and application of cisplatin-containing medicine

The invention provides a cisplatin-containing medicine, a preparation method of the cisplatin-containing medicine, a medicine composition and application. The medicine comprises a nucleic acid nanoparticle and cisplatin mounted on the nucleic acid nanoparticle; and the nucleic acid nanoparticle comprises a nucleic acid structural domain, the nucleic acid structural domain comprises a sequence a, asequence b and a sequence c, the sequence a comprises a sequence a1 or a sequence obtained after insertion, deletion or substitution of at least one base of the sequence a1, the sequence b comprisesa sequence b1 or a sequence obtained after insertion, deletion or substitution of at least one base of the sequence b1, and the sequence c comprises a sequence c1 or a sequence obtained after insertion, deletion or substitution of at least one base of the sequence c1. After target head modification, the nucleic structural domain of the cisplatin-containing medicine has better targeting ability, can stably deliver cisplatin and has high reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

Methotrexate-containing medicine, preparation method, medicinal composition and application thereof

The invention provides a methotrexate-containing medicine, a preparation method, a medicinal composition and application thereof. The medicine comprises nucleic acid nanoparticles and methotrexate, wherein the methotrexate is mounted on the nucleic acid nanoparticles; the nucleic acid nanoparticles comprise nucleic acid structural domains, including a sequences, b sequences and c sequences; each asequence contains an a1 sequence or a sequence having at least one basic group inserted, lost or substituted on the a1 sequence; each b sequence contains a b1 sequence or a sequence having at least one basic group inserted, lost or substituted on the b1 sequence; and each c sequence contains a c1 sequence or a sequence having at least one basic group inserted, lost or substituted on the c1 sequence. After the nucleic acid structural domains are subjected to target head modification, the methotrexate-containing medicine has relatively good target performance, can be used for stably deliveringthe methotrexate and has high reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

Medicine containing aspirin, its preparation method, pharmaceutical composition and application

The application provides an aspirin-containing medicine, its preparation method, pharmaceutical composition and application. The drug includes nucleic acid nanoparticles and aspirin, and aspirin is mounted on the nucleic acid nanoparticles; the nucleic acid nanoparticles include a nucleic acid domain, the nucleic acid domain includes a sequence, b sequence and c sequence, and the a sequence includes a1 sequence or a1 sequence occurs at least A sequence of base insertion, deletion or substitution, b sequence contains b1 sequence or b1 sequence has at least one base insertion, deletion or substitution, c sequence contains c1 sequence or c1 sequence has at least one base insertion, deletion or substitution the sequence of. The aspirin-containing medicine provided by the present application, after the nucleic acid domain is modified by the target head, can have better targeting, can deliver aspirin stably, and has high reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

Drug containing pirarubicin, preparation method for drug, pharmaceutical composition and application of drug

The application provides a drug containing pirarubicin, a preparation method for the drug, a pharmaceutical composition and application of the drug. The drug comprises a nucleic acid nanoparticle andthe pirarubicin, and the pirarubicin is deposited on the nucleic acid nanoparticle; the nucleic acid nanoparticle includes a nucleic acid domain; the nucleic acid domain includes an a sequence, a b sequence and a c sequence; the a sequence includes an a1 sequence or a sequence of insertion, deletion or substitution of at least one base of the a1 sequence; the b sequence includes a b1 sequence or asequence of insertion, deletion or substitution of at least one base of the b1 sequence; and the c sequence includes a c1 sequence or a sequence of insertion, deletion or substitution of at least onebase of the c1 sequence. After the nucleic acid domain is modified by a target head, the drug containing the pirarubicin has a relatively good targeting property, can stably deliver the pirarubicin,and has very high reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

Cisplatin-containing medicine, preparation method, pharmaceutical composition and application thereof

The present application provides a cisplatin-containing medicine, its preparation method, pharmaceutical composition and application. The drug includes nucleic acid nanoparticles and cisplatin, and the cisplatin is mounted on the nucleic acid nanoparticles; the nucleic acid nanoparticles include a nucleic acid domain, the nucleic acid domain includes a sequence, b sequence and c sequence, and the a sequence includes a1 sequence or a1 sequence The sequence with at least one base insertion, deletion or substitution, the b sequence contains the b1 sequence or the b1 sequence has at least one base insertion, deletion or substitution, the c sequence contains the c1 sequence or the c1 sequence has at least one base insertion, deletion or a sequence of substitutions. The cisplatin-containing drug provided by the present application, after its nucleic acid domain is modified by the target head, can have better targeting, can deliver cisplatin stably, and has high reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

Cytarabine-containing medicine, and preparation method, pharmaceutical composition and an application thereof

The invention provides a cytarabine-containing medicine, and a preparation method, a pharmaceutical composition and an application thereof. The medicine comprises a nucleic acid nanoparticle and cytarabine, and the cytarabine is loaded on the nucleic acid nanoparticle; and the nucleic acid nanoparticle comprises a nucleic acid structural domain, the nucleic acid structural domain comprises a sequence a, a sequence b and a sequence c, the sequence a comprises a sequence a1 or a sequence obtained by inserting, deleting or substituting at least one base in the sequence a1, the sequence b comprises a sequence b1 or a sequence obtained by inserting, deleting or substituting at least one base in the sequence b1, and the sequence c comprises a sequence c1 or a sequence obtained by inserting, deleting or substituting at least one base in the sequence c1. After the nucleic acid structural domain is modified with a target head, the cytarabine-containing medicine has a good targeting property, can stably deliver the cytarabine, and has a very high reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

Medicine containing epirubicin, preparation method thereof, pharmaceutical composition and application thereof

The present application provides a medicine containing epirubicin, its preparation method, pharmaceutical composition and application. The drug includes nucleic acid nanoparticles and epirubicin, and epirubicin is mounted on the nucleic acid nanoparticles; the nucleic acid nanoparticles include a nucleic acid domain, the nucleic acid domain includes a sequence, b sequence and c sequence, and the a sequence includes a1 The sequence or a1 sequence has at least one base insertion, deletion or substitution sequence, the b sequence contains the b1 sequence or the b1 sequence has at least one base insertion, deletion or substitution, and the c sequence contains the c1 sequence or the c1 sequence has at least one base substitution. Sequences of insertions, deletions or substitutions. The epirubicin-containing medicine provided by the present application can have good targeting ability after the nucleic acid domain is modified by the target head, can deliver epirubicin stably, and has high reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

Medicine containing idarubicin, its preparation method, pharmaceutical composition and its application

The application provides a medicine containing idarubicin, its preparation method, pharmaceutical composition and application. The drug includes nucleic acid nanoparticles and idarubicin, and idarubicin is mounted on the nucleic acid nanoparticles; the nucleic acid nanoparticles include a nucleic acid domain, the nucleic acid domain includes a sequence, b sequence and c sequence, and the a sequence includes a1 The sequence or a1 sequence has at least one base insertion, deletion or substitution sequence, the b sequence contains the b1 sequence or the b1 sequence has at least one base insertion, deletion or substitution, and the c sequence contains the c1 sequence or the c1 sequence has at least one base substitution. Sequences of insertions, deletions or substitutions. The idarubicin-containing medicine provided by the present application, after the nucleic acid domain is modified by the target head, can have better targeting, can deliver idarubicin stably, and has high reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

Mitoxantrone-containing medicine, and preparation method, pharmaceutical composition and application thereof

The invention provides a mitoxantrone-containing medicine, and a preparation method, a pharmaceutical composition and an application thereof. The medicine comprises a nucleic acid nanoparticle and mitoxantrone, and the mitoxantrone is loaded on the nucleic acid nanoparticle; and the nucleic acid nanoparticle comprises a nucleic acid structural domain, the nucleic acid structural domain comprises asequence a, a sequence b and a sequence c, the sequence a comprises a sequence a1 or a sequence obtained by inserting, deleting or substituting at least one base in the sequence a1, the sequence b comprises a sequence b1 or a sequence obtained by inserting, deleting or substituting at least one base in the sequence b1, and the sequence c comprises a sequence c1 or a sequence obtained by inserting, deleting or substituting at least one base in the sequence c1. After the nucleic acid structural domain is modified with a target head, the mitoxantrone-containing medicine has a good targeting property, can stably deliver the mitoxantrone, and has a very high reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

Gemcitabine-containing medicine and preparation method thereof, and pharmaceutical composition and application thereof

The application provides a gemcitabine-containing medicine and a preparation method thereof, and a pharmaceutical composition and an application thereof. The medicine comprises nucleic acid nanoparticles and gemcitabine, and besides, the gemcitabine is carried on the nucleic acid nanoparticles; and the nucleic acid nanoparticles comprise a nucleic acid domain, the nucleic acid domain comprises a sequence a, a sequence b and a sequence c, the sequence a comprises a sequence a1 or a sequence of the sequence a1 with at least one base insertion, deletion or substitution, the sequence b comprises asequence b1 or a sequence of the sequence b1 with at least one base insertion, deletion or substitution, and the sequence c comprises a sequence c1 or a sequence of the sequence c1 with at least onebase insertion, deletion or substitution. After the nucleic acid structural domain is modified by a target head, the provided gemcitabine-containing medicine has relatively good targeting property, can stably deliver the gemcitabine and is very high in reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

Paclitaxel-containing medicine, and preparation method, pharmaceutical composition and application thereof

The invention provides a paclitaxel-containing medicine, and a preparation method, a pharmaceutical composition and an application thereof. The medicine comprises a nucleic acid nanoparticle and paclitaxel, and the paclitaxel is loaded on the nucleic acid nanoparticle; and the nucleic acid nanoparticle comprises a nucleic acid structural domain, the nucleic acid structural domain comprises a sequence a, a sequence b and a sequence c, the sequence a comprises a sequence a1 or a sequence obtained by inserting, deleting or substituting at least one base in the sequence a1, the sequence b comprises a sequence b1 or a sequence obtained by inserting, deleting or substituting at least one base in the sequence b1, and the sequence c comprises a sequence c1 or a sequence obtained by inserting, deleting or substituting at least one base in the sequence c1. After the nucleic acid structural domain is modified with a target head, the paclitaxel-containing medicine has a good targeting property, can stably deliver the paclitaxel, and has a very high reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

Medicine containing aspirin, preparation method of medicine containing aspirin, medicine composition and application

The application provides medicine containing aspirin, a preparation method of the medicine containing aspirin, a medicine composition and application. The medicine comprises nucleic acid nanoparticlesand the aspirin, wherein the aspirin is hung and loaded on the nucleic acid nanoparticles; the nucleic acid nanoparticles comprise a nucleic acid structural domain; the nucleic acid structural domaincomprises a sequence a, a sequence b and a sequence c; the sequence a comprises a sequence a1 or a sequence obtained by performing insertion, deletion or substitution of at least one base on the sequence a1; the sequence b comprises a sequence b1 or a sequence obtained by performing insertion, deletion or substitution of at least one base on the sequence b1; and the sequence c comprises a sequence c1 or a sequence obtained by performing insertion, deletion or substitution of at least one base on the sequence c1. The medicine containing aspirin provided by the invention has the advantages thatafter the nucleic acid structural domain is modified by a target head, good targeting performance is realized; the aspirin can be stably delivered; and the reliability is very high.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

Medicine containing epirubicin, preparation method, medicine composition and application thereof

The application provides a medicine containing epirubicin, a preparation method, a medicine composition and application thereof. The medicine comprises nucleic acid nanoparticles and the epirubicin, and the epirubicin is mounted on nucleic acid nanoparticles. Nucleic acid nanoparticles include a nucleic acid domain, and the nucleic acid domain contains a a sequence, a b sequence and a c sequence.The a sequence contains a a1 sequence or a sequence that at least one base insertion, base deletion or base substitution occurs in a1 sequence. The b sequence contains a b1 sequence or a sequence thatat least one base insertion, base deletion or base substitution occurs in b1 sequence. The c sequence contains a c1 sequence or a sequence that at least one base insertion, base deletion or base substitution occurs in c1 sequence. After the nucleic acid domain is modified by the target head, the medicine containing epirubicin provided by the present application has better targeting, can stably delivers epirubicin, and has high reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

Flavones-containing medicine, preparation method thereof, medicine composition and application

The invention provides a flavones-containing medicine, a preparation method thereof, a medicine composition and application. The medicine comprises nucleic acid nanoparticles and flavones, wherein theflavones are hung on the nucleic acid nanoparticles; the nucleic acid nanoparticles comprise a nucleic acid structure domain; the nucleic acid structure domain comprises a sequence a, a sequence b and a sequence c; the sequence a comprises a sequence a1 or a sequence that at least one base group is inserted, deleted or replaced in the sequence a1; the sequence b comprises a sequence b1 or a sequence that at least one base group is inserted, deleted or replaced in the sequence b1; and the sequence comprises a sequence c1 or a sequence that at least one base group is inserted, deleted or replaced in the sequence c1. After target head modification on the nucleic acid structure domain, the flavones-containing medicine provided by the invention has good targeting performance, is capable of stably delivering the flavones and is high in reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

5-fluorouracil-containing medicine and preparation method thereof, and pharmaceutical composition and application thereof

The application provides a 5-fluorouracil-containing medicine and a preparation method thereof, and a pharmaceutical composition and an application thereof. The medicine comprises nucleic acid nanoparticles and 5-fluorouracil, and besides, the 5-fluorouracil is carried on the nucleic acid nanoparticles; and the nucleic acid nanoparticles comprise a nucleic acid domain, the nucleic acid domain comprises a sequence a, a sequence b and a sequence c, the sequence a comprises a sequence a1 or a sequence of the sequence a1 with at least one base insertion, deletion or substitution, the sequence b comprises a sequence b1 or a sequence of the sequence b1 with at least one base insertion, deletion or substitution, and the sequence c comprises a sequence c1 or a sequence of the sequence c1 with at least one base insertion, deletion or substitution. After the nucleic acid structural domain is modified by a target head, the provided 5-fluorouracil-containing medicine has relatively good targetingproperty, can stably deliver the 5-fluorouracil and is very high in reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

Medicine containing methotrexate, its preparation method, pharmaceutical composition and application thereof

The application provides a medicine containing methotrexate, its preparation method, pharmaceutical composition and application. The drug includes nucleic acid nanoparticles and methotrexate, and the methotrexate is mounted on the nucleic acid nanoparticles; the nucleic acid nanoparticles include a nucleic acid domain, the nucleic acid domain includes a sequence, b sequence and c sequence, and the a sequence includes a1 sequence or a1 sequence with at least one base insertion, deletion or substitution, b sequence contains b1 sequence or b1 sequence with at least one base insertion, deletion or substitution, c sequence contains c1 sequence or c1 sequence with at least one base sequences of insertions, deletions, or substitutions. The drug containing methotrexate provided by the present application, after the nucleic acid structure domain is modified by the target head, can have better targeting, can deliver methotrexate stably, and has high reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

Lenalidomide-containing medicine, and preparation method, pharmaceutical composition and application thereof

The invention provides a lenalidomide-containing medicine, and a preparation method, a pharmaceutical composition and an application thereof. The medicine comprises a nucleic acid nanoparticle and lenalidomide, and the lenalidomide is loaded on the nucleic acid nanoparticle; and the nucleic acid nanoparticle comprises a nucleic acid structural domain, the nucleic acid structural domain comprises asequence a, a sequence b and a sequence c, the sequence a comprises a sequence a1 or a sequence obtained by inserting, deleting or substituting at least one base in the sequence a1, the sequence b comprises a sequence b1 or a sequence obtained by inserting, deleting or substituting at least one base in the sequence b1, and the sequence c comprises a sequence c1 or a sequence obtained by inserting, deleting or substituting at least one base in the sequence c1. After the nucleic acid structural domain is modified with a target head, the lenalidomide-containing medicine has a good targeting property, can stably deliver the lenalidomide, and has a very high reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

Docetaxel-containing medicine, and preparation method, pharmaceutical composition and application thereof

The invention provides a docetaxel-containing medicine, and a preparation method, a pharmaceutical composition and application thereof. The medicine comprises nucleic acid nanoparticles and docetaxel,and the docetaxel is mounted on the nucleic acid nanoparticles; the nucleic acid nanoparticles comprise a nucleic acid domain, the nucleic acid domain comprises a sequence a, a sequence b and a sequence c. The sequence a comprises a sequence a1 or a sequence in which at least one base is inserted, deleted or replaced in the sequence a1; the sequence b comprises a sequence b1 or a sequence in which at least one base is inserted, deleted or replaced in the sequence b1; and the sequence c comprises a sequence c1 or a sequence in which at least one base is inserted, deleted or replaced in the sequence c1. After the nucleic acid domain of the docetaxel-containing medicine is modified by a target head, the docetaxel-containing medicine provided by the invention has relatively good targeting property, can stably deliver the docetaxel, and is very high in reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD

Medicine containing 10-hydroxycamptothecin, its preparation method, pharmaceutical composition and application thereof

The application provides a medicine containing 10-hydroxycamptothecin, its preparation method, pharmaceutical composition and application. The drug includes nucleic acid nanoparticles and 10-hydroxycamptothecin, and 10-hydroxycamptothecin is mounted on the nucleic acid nanoparticles; the nucleic acid nanoparticles include a nucleic acid domain, and the nucleic acid domain includes a sequence, b sequence and c sequence, The a sequence includes the a1 sequence or the sequence in which at least one base insertion, deletion or substitution occurs in the a1 sequence, the b sequence includes the b1 sequence or the sequence in which at least one base insertion, deletion or substitution occurs in the b1 sequence, and the c sequence includes the c1 sequence or the c1 sequence A sequence in which at least one base has been inserted, deleted or substituted. The drug containing 10-hydroxycamptothecin provided by the present application, after the nucleic acid domain is modified by the target head, can have better targeting, can stably deliver 10-hydroxycamptothecin, and has high reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products